A case–control study of single-nucleotide variants in microRNA biogenesis genes (AGO1 and GEMIN4) in people with primary immune thrombocytopenia

Egyptian Journal of Medical Human Genetics

Table 3 rs636832 A/G genotypes frequencies and ITP characteristics

	rs636832 A/G genotypes						p-value *	Recessive model				p-value *
	AA		AG		GG			AA + AG		GG
	N (5)	%	N (22)	%	N (73)	%		N (27)	%	N (73)	%
Sex
Male	1	20	3	13.64	9	12.33	0.881	4	14.81	9	12.33	0.743
Female	4	80	19	86.36	64	87.67		23	85.19	64	87.67
Phase
Newly diagnosed	2	40	8	36.36	21	28.77	0.044*	10	37.04	21	28.77	0.304
Persistent	3	60	3	13.64	10	13.70		6	22.22	10	13.70
Chronic	0	0	11	50	42	57.53		11	40.74	42	57.53
Cutaneous bleeding
Petechia and Purpura	5	100	21	95.45	72	98.63	0.613	26	96.30	72	98.63	0.459
Ecchymosis	1	20	13	59.09	29	39.73	0.155	14	51.85	29	39.73	0.277
Non-cutaneous bleeding
Epistaxis	2	40	9	40.91	29	39.73	0.993	11	40.74	29	39.73	0.927
Vaginal Bleeding	2	40	7	31.82	24	32.88	0.939	9	33.33	24	32.88	0.966
Bleeding/gums	2	40	8	36.36	28	38.36	0.981	10	37.04	28	38.36	0.904
Grade of bleeding
1	2	40	8	36.36	28	38.36	0.718	10	37.04	28	38.36	0.833
2	0	0	5	22.73	10	13.70		5	18.52	10	13.70
3	3	60	9	40.91	35	47.95		12	44.44	35	47.95
Treatment modalities
Corticosteroid	4	80	18	81.82	55	75.34	0.808	22	81.84	55	75.34	0.517
Immunosuppressive	3	60	5	22.73	26	35.62	0.242	8	29.63	26	35.62	0.575
TPO-RA agonist	0	0	0	0	3	4.11	0.564	0	0	3	4.11	0.285
Splenectomy	0	0	2	9.09	8	10.96	0.722	2	7.41	8	10.96	0.599
Treatment Response
No response	0	0	0	0	5	6.85	0.378	0	0	5	6.85	0.163
Response	5	100	22	100	68	93.15		27	100	68	93.15
Death	0	0	0	0	1	1.37	0.830	0	0	1	1.37	0.541